12
Participants
Start Date
January 14, 2014
Primary Completion Date
September 1, 2015
Study Completion Date
October 13, 2015
LGX818
LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
University of Pennsylvania Presbyterian Medical Center University of Pennsylvania, Philadelphia
Shenandoah Oncology Shenadoah Oncology (2), Winchester
Florida Cancer Specialists Florida Cancer Specialists (31, Fort Myers
Alabama Oncology St. Vincent's Birmingham, Birmingham
Genesis Cancer Services, Zanesville
Sanford Research Sanford Health, Sioux Falls
Lurie Children's Hospital of Chicago Developmental Therapeutics, Chicago
Highlands Oncology Group Highlands Oncology Group (22), Fayetteville
Oncology Consultants Oncology Group, Houston
Utah Cancer Specialists Utah Cancer Specialists (11), Salt Lake City
Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas
Yale University School of Medicine Smilow Cancer Hospital, New Haven
Whittingham Cancer Center Norwalk Hospital, Norwalk
Lead Sponsor
Pfizer
INDUSTRY